The company will build a $50 million facility in Tamarac to manufacture pharmaceuticals, functional foods and nutraceutical products at its newly renovated facility, bringing 100 jobs.
The company will provide patients and end-consumers with a new delivery system for liquid nutraceutical and pharmaceutical products manufactured with Blow-Fill-Seal technology. This company said that the new delivery system will reduce accidental over-the-counter overdoses which are responsible for more than 15,000 annual deaths in the United States alone.
In addition to Greater Fort Lauderdale, other locations under consideration included Madrid, Spain, and Atlanta, Georgia. The company cited connectivity to foreign markets via the port and airport, a growing life sciences cluster and focus on contract manufacturing in the pharmaceutical and neutraceutical industries, as well as the ability to attract top talent due to quality of life as top advantages for relocation to Broward.
“We are happy to say that we have begun another chapter in our company’s history with our new manufacturing site in Broward County. Our new facility will not only provide jobs for the local community, but it will support Florida’s growing Life Science industry as well,” said Reinaldo Santa Marta, CEO of Unipharma.
The addition of these pharmaceutical manufacturing jobs to the local economy helped secure Unipharma a total of $500,000 in performance based incentives from the state, county and city through the State of Florida’s Qualified Target Industry tax incentive program over the next seven years. Additionally, the company will make a $50 million capital investment in facilities and equipment between now and 2015.
